Jeffrey Stein - Cidara Therapeutics President
| CDTX Stock | USD 22.47 0.63 2.73% |
President
Dr. Jeffrey L. Stein, Ph.D. is President, Chief Executive Officer, Principal Financial Officer, Director of the Company. Since January 2014. Prior to joining us, Dr. Stein was the President and Chief Executive Officer of Trius Therapeutics, Inc., a publiclytraded pharmaceutical company, until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Dr. Stein was also a venture partner at Sofinnova Ventures, a biotech VC fund, from 2005 to 2010. Prior to joining Sofinnova, Dr. Stein was cofounder and Chief Scientific Officer at Quorex Pharmaceuticals, Inc., a private pharmaceutical company, from 1999 until its acquisition by Pfizer Pharmaceuticals, Inc. in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein currently serves on the board of directors of Great Lakes Pharmaceuticals, Inc., a private biopharmaceutical company, and Paratek Pharmaceuticals, a publiclytraded biopharmaceutical company. Dr. Stein holds a B.S. in marine biology and an M.S. in biology from California State UniversityLong Beach and a Ph.D. in marine biology from the University of California, San Diego since 2018.
| Age | 70 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Address | 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121 |
| Phone | 858 752 6170 |
| Web | https://www.cidara.com |
Latest Insider Transactions
Stein conducted his postdoctoral research in bacterial genetics as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology.Jeffrey Stein Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Stein against Cidara Therapeutics stock is an integral part of due diligence when investing in Cidara Therapeutics. Jeffrey Stein insider activity provides valuable insight into whether Cidara Therapeutics is net buyers or sellers over its current business cycle. Note, Cidara Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cidara Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Stein over six months ago Acquisition by Jeffrey Stein of 8000 shares of Cidara Therapeutics at 13.21 subject to Rule 16b-3 | ||
Jeffrey Stein over a year ago Acquisition by Jeffrey Stein of 1040000 shares of Cidara Therapeutics at 0.6849 subject to Rule 16b-3 | ||
Jeffrey Stein over a year ago Purchase by Jeffrey Stein of 50000 shares of Cidara Therapeutics | ||
Jeffrey Stein over a year ago Acquisition by Jeffrey Stein of 271750 shares of Cidara Therapeutics subject to Rule 16b-3 |
Cidara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4046) % which means that it has lost $0.4046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1959) %, meaning that it created substantial loss on money invested by shareholders. Cidara Therapeutics' management efficiency ratios could be used to measure how well Cidara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2025. Return On Capital Employed is likely to rise to -1.01 in 2025. At this time, Cidara Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 20.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 2.8 M in 2025.Similar Executives
| Found 3 records | PRESIDENT Age | ||
| Leslie Robbins | CytomX Therapeutics | N/A | |
| Rafael Andino | Clearside Biomedical | 60 | |
| Armand Girard | GlycoMimetics | 55 | |
Management Performance
| Return On Equity | -2.2 | ||||
| Return On Asset | -0.4 |
Cidara Therapeutics Leadership Team
Elected by the shareholders, the Cidara Therapeutics' board of directors comprises two types of representatives: Cidara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cidara. The board's role is to monitor Cidara Therapeutics' management team and ensure that shareholders' interests are well served. Cidara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cidara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carol Waldo, VP Assurance | ||
| Preetam MBA, Principal Officer | ||
| James Balkovec, VP Research | ||
| Jeffrey Stein, Chief Executive and President and Executive Director | ||
| Taylor Sandison, Acting Chief Medical Officer | ||
| SPHR CCP, Senior Culture | ||
| Jim MBA, Chief Officer | ||
| Kevin Forrest, Founder, CFO, COO and Treasurer | ||
| Laura Navalta, Senior Vice President - Clinical Operations | ||
| Shane Ward, COO Secretary | ||
| Leslie Tari, Chief Officer | ||
| Shane JD, COO Secretary | ||
| Les Tari, Vice President - Discovery Research | ||
| MD JD, Interim Development | ||
| MPH MD, Chief Officer | ||
| Frank MBA, Chief Officer |
Cidara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cidara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.2 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (71.54) % | ||||
| Current Valuation | 66.78 M | ||||
| Shares Outstanding | 10.95 M | ||||
| Shares Owned By Insiders | 1.37 % | ||||
| Shares Owned By Institutions | 69.43 % | ||||
| Number Of Shares Shorted | 181.99 K | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 1.55 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.